Navigation Links
Vion Pharmaceuticals Reports 2009 First Quarter Results
Date:5/11/2009

Company to hold Conference Call on May 14, 2009

NEW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the first quarter of 2009.

The Company reported a net loss of $4.3 million, or $0.54 per share, for the quarter ended March 31, 2009, compared with a net loss of $8.2 million, or $1.14 per share, for the same 2008 period. Weighted-average common shares outstanding for the three months ended March 31, 2009 and March 31, 2008 were 7.9 million and 7.2 million, respectively.

The Company reported ending the quarter with $30.0 million in cash and cash equivalents. Based on its current operating plan, management estimates that its existing cash and cash equivalents will be sufficient to fund operations through the first quarter of 2010.

In February 2009, the Company submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead anticancer agent Onrigin (laromustine) Injection for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). In April 2009, the Company announced that the FDA had accepted the NDA for review and that it had been assigned an end user fee date of December 12, 2009 for a decision on approval by the FDA.

Alan Kessman, Chief Executive Officer, commented, "We are continuing to interact with the FDA on our NDA with the objective of receiving approval for Onrigin in its first indication in the U.S. by the end of 2009."

Conference Call

The Company will hold a conference call at 8:30 a.m. Eastern Time on May 14, 2009 to discuss its operations and financial results.

To participate in the conference call, please dial (866) 271-6130 in the U.S. ((617) 213-8894 for international callers) at lea
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
5. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
6. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
8. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
9. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
10. Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... of vegetables in childhood lower risk// of stroke.This link ... a very interesting study published in the journal Heart. ... not just due to exposure to risk factors in ... an entire lifetime. Previous studies have suggested that diets ...
... with the help of anti fungal medication itraconazole can ... Manchester have broken new grounds in asthma treatment by ... bronchopulmonary aspergillosis, which is a form of asthma. , ... treated with steroids or drugs that have equally disastrous ...
... the use of strontium ranelate to be used for treating ... drug it is important to observe the changes in the ... Journal has said that the drug strontium ranelate have an ... effect can be used in advantage of the treatment procedure. ...
... researchers at Massachusetts General Hospital// and the Harvard School of ... may lower the risk of type II diabetes in men. ... produce enough insulin or the cells ignore the insulin. Insulin ... sugar. Type II diabetes typically occurs in individuals older than ...
... stomach infections caused by Helicobacter pylori might be ... pylori are common bacteria that reside in the ... infections. Previous research had connected the bacteria with ... ischemic heart disease. ,Researchers have tested patients ...
... common genetical variants that increase the risk for developing// ... condition in which kidneys of the body are unable ... waste balance that is part of the metabolism practice. ... that can lead to toxicity of the body. Chronic ...
Cached Medicine News:Health News:Association between childhood diet and stroke 2
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... CryoLife, Inc. (NYSE: CRY ), an implantable ... Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical ... angina resulting from diffuse coronary artery disease, today announced ... approved a definitive agreement under which CryoLife will acquire ...
... Pharmaceuticals, Inc., has been informed by the National Institute ... the National Institutes of Health that patient enrollment has ... nonalcoholic steatohepatitis (NASH), which will evaluate Intercept,s first-in-class farnesoid ... novel therapy for NASH. The FXR Ligand NASH Treatment ...
Cached Medicine Technology:CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 2CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 3CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 4CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 5CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 7CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 8CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 9CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 10CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 12CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 13CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 14CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 15CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 16CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 17CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 18Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH 2Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH 3
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Bra...
Bra With Cups...
Medicine Products: